Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lian-Sheng Li

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Journal of Medicinal Chemistry|October 29, 2004
Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devicesLian-Sheng Li, Christoph Rader, Masayuki Matsushita, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 21, 2007
Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activationSunny Abraham, Fang Guo, Lian-Sheng Li, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|September 21, 2004
Aldolase antibody activation of prodrugs of potent aldehyde-containing cytotoxics for selective chemotherapySubhash C Sinha, Lian-Sheng Li, Shin-Ichi Watanabe, et al.
Nature Structural & Molecular Biology|May 16, 2018
The reactivity-driven biochemical mechanism of covalent KRAS<sup>G12C</sup> inhibitorsRasmus Hansen, Ulf Peters, Anjali Babbar, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|February 26, 2016
Phosphorylation of Nonmuscle Myosin Light Chain Promotes Endothelial Injury in Hyperlipidemic Rats Through a Mechanism Involving Downregulation of Dimethylarginine Dimethylaminohydrolase 2Yan Wu, Jie-Jie Zhang, Ting-Bo Li, et al.
Science Translational Medicine|September 20, 2019
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancerMiriam Molina-Arcas, Christopher Moore, Sareena Rana, et al.
Cancer Discovery|January 8, 2016
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive StateMatthew P Patricelli, Matthew R Janes, Lian-Sheng Li, et al.
The Journal of Biological Chemistry|January 1, 2013
Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte functionLomon So, Sung Su Yea, Jean S Oak, et al.
Bioorganic & Medicinal Chemistry Letters|January 30, 2008
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 2: Variation of the 2- and 6-pyridazinone substituentsYuefen Zhou, Lian-Sheng Li, Peter S Dragovich, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2008
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 1: exploration of 7'-substitution of benzothiadiazineYuefen Zhou, Stephen E Webber, Douglas E Murphy, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Journal of Medicinal Chemistry|October 29, 2004
Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devicesLian-Sheng Li, Christoph Rader, Masayuki Matsushita, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 21, 2007
Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activationSunny Abraham, Fang Guo, Lian-Sheng Li, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|September 21, 2004
Aldolase antibody activation of prodrugs of potent aldehyde-containing cytotoxics for selective chemotherapySubhash C Sinha, Lian-Sheng Li, Shin-Ichi Watanabe, et al.
Nature Structural & Molecular Biology|May 16, 2018
The reactivity-driven biochemical mechanism of covalent KRAS<sup>G12C</sup> inhibitorsRasmus Hansen, Ulf Peters, Anjali Babbar, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|February 26, 2016
Phosphorylation of Nonmuscle Myosin Light Chain Promotes Endothelial Injury in Hyperlipidemic Rats Through a Mechanism Involving Downregulation of Dimethylarginine Dimethylaminohydrolase 2Yan Wu, Jie-Jie Zhang, Ting-Bo Li, et al.
Science Translational Medicine|September 20, 2019
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancerMiriam Molina-Arcas, Christopher Moore, Sareena Rana, et al.
Cancer Discovery|January 8, 2016
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive StateMatthew P Patricelli, Matthew R Janes, Lian-Sheng Li, et al.
The Journal of Biological Chemistry|January 1, 2013
Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte functionLomon So, Sung Su Yea, Jean S Oak, et al.
Bioorganic & Medicinal Chemistry Letters|January 30, 2008
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 2: Variation of the 2- and 6-pyridazinone substituentsYuefen Zhou, Lian-Sheng Li, Peter S Dragovich, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2008
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 1: exploration of 7'-substitution of benzothiadiazineYuefen Zhou, Stephen E Webber, Douglas E Murphy, et al.
Pageof 4